...by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus shot and weak demand for COVID-19 vaccines.
Sage Therapeutics #SG7 (NASDAQ:SAGE) stock gained 36% after the company confirmed that biotech major Biogen (NASDAQ:BIIB), down 0.1%, has made a nonbinding proposal to...